

# Parkinson's disease guideline committee meeting

Date: 28 November 2016

Location: NICE offices, Manchester

Minutes: Final

Committee members present	
Paul Cooper (Chair)	Present for all
Janine Barnes (JB)	Present for all
Alistair Church (AC)	Present for all
Debbie Davies (DD)	Present for all
Robin Fackrell (RF)	Present for all
Richard Grunewald (RG)	Present for all
Graham Lennox (GL)	Present for all
Fiona Lindop (FL)	Present for all
Jane Little (JL)	Present for all
Lynne Osbourne (LO)	Present for all
Paul Shotbolt (PS)	Present for all
Matthew Sullivan (MS)	Present for all
Richard Walker (RW)	Present for all
Beverly Sheaf (BS) (co-opted)	Present from item 3
Nicholas Miller (NM) (co-opted)	Present for all
Julian Evans (JE) (co-opted)	Present for item 1 - 3

In Attendance:		
Sue Spiers (SS)	Associate Director	Present for all
Gabriel Rogers (GR)	Health Economist	Present until item 4
Joshua Pink (JP)	Technical Advisor	Present for all
Aimely Lee (AL)	Technical Analyst	Present for all
Daniel Davies (DaD)	Project Manager	Present for all
Louise Bate (LB)	Senior Medicines Adviser	Present for all
Ben Doak (BD)	NICE Commissioning Manager	Present for all
Sarah Palombella	Editor	Present for all
lan Mather	Business Analyst	Present for all
Les Hayes	Business Analyst	Present for all

#### 4.0.3 DOC Cmte minutes

Observers:	
Jess Fielding	Public Involvement Advisor
Mark Rasburn	Public Involvement Advisor

Committee member apologies:
Clare Johnson (CJ) (co-opted)
Amanda Wardle (AW) (co-opted)
Robin Fackrell (RF)
Ivan Bennett (IB)

### 1. Welcome, introductions, minutes, Dol and matters arising

The Chair asked those present to declare any conflicts of interest relevant to the areas being discussed or potential new conflicts. No new declarations were made.

It was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The committee reviewed the minutes of the previous meeting and agreed they were an accurate record of the discussions.

### 2. Resource Impact update

IM and LH provided an overview of the resource impact work that has been carried out for the guideline, and queried a few points with the committee

### 3. Stakeholder Consultation comments: Advanced Parkinson's disease

GR led a discussion with the committee on the stakeholder comments regarding advanced Parkinson's disease following consultation. The committee agreed the responses to the individual stakeholder comments and any necessary changes to the guideline and / or recommendations.

### 4. Stakeholder Consultation comments: Impulse Control disorders

AL led a discussion with the committee on the stakeholder comments regarding impulse control disorders following consultation. The committee agreed the responses to the individual stakeholder comments and any necessary changes to the guideline and / or recommendations.

# 5. Stakeholder Consultation comments: Pharmacological management

### 4.0.3 DOC Cmte minutes

AL led a discussion with the committee on the stakeholder comments regarding pharmacological management following consultation. The committee agreed the responses to the individual stakeholder comments and any necessary changes to the guideline and / or recommendations.

### 6. Stakeholder Consultation comments: Non-pharmacological management

AL led a discussion with the committee on the stakeholder comments regarding non-pharmacological management following consultation. The committee agreed the responses to the individual stakeholder comments and any necessary changes to the guideline and / or recommendations.

## 7. Publication process

Due to time constraints, information regarding the publication process was agreed to be circulated following the meeting.

### 8. AOB

PC briefly summarised the meeting, and advised that updated versions of the guideline would be circulated to the committee for their comment.

PC thanked the committee for their work and involvement on the guideline and encouraged them to get involved in future work with NICE.